Lantheus
LNTH
Collegium Pharmaceutical
COLL
Constellation Brands
STZ
4
Halozyme Therapeutics
HALO
5
AIRPORTS OF THAILAND PUBLIC CO UNSP ADR EACH REP 10 ORD SHS
AIPUY
US Stock MarketDetailed Quotes
IMAB I-Mab
- 0.812
- -0.045-5.24%
Close Mar 10 16:00 ET
66.18MMarket Cap-0.85P/E (TTM)
0.860High0.810Low127.92KVolume0.860Open0.857Pre Close106.23KTurnover0.27%Turnover RatioLossP/E (Static)81.50MShares2.00052wk High0.30P/B38.98MFloat Cap0.76052wk Low--Dividend TTM48.01MShs Float85.400Historical High--Div YieldTTM5.84%Amplitude0.760Historical Low0.830Avg Price1Lot Size
About I-Mab Company
I-Mab operates as a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel or differentiated biologics to treat diseases with unmet medical needs, particularly cancers and autoimmune disorders. The company was founded by Jingwu Zang on June 30, 2016 and is headquartered in Rockville, MD.
Company Profile
SymbolIMAB
Company NameI-Mab
Listing DateJan 17, 2020
Issue Price14.00
Founded2016
CEODr. Xi-Yong Sean Fu
MarketNASDAQ
Employees220
Securities TypeDR
ADS Ratio10.0 : 23.0
Fiscal Year Ends12-31
Address2440 Research Boulevard,Suite 400
CityRockville
ProvinceMaryland
CountryUnited States of America
Zip Code20850
Phone1-240-745-6330
Company Executives
- Name
- Position
- Salary
- Dr. Xi-Yong Sean Fu
- Chief Executive Officer and Director
- --
- Joseph Skelton
- Chief Financial Officer
- --
- Dr. Phillip Dennis, M.D.
- Chief Medical Officer
- --
- Wei Fu
- Chairman of the Board
- --
- Chia-hung Conor Yang
- Independent Director
- --
- Lielie Zhang
- Independent Director
- --
- Chun Kwok Alan Au
- Independent Director
- --
Trending Stocks
Discussing
FOMC leaves rates unchanged, how will you adjust your portfolio?
FOMC left the target Federal Funds rate unchanged at at target of 4.25%-4.5%, how will you adjust your portfolio?
Moo Live
Jan 30 03:25
FOMC Press Conference, January 29, 2025